Clinical-stage biopharmaceutical company using its DELigase platform to discover targeted protein degradation and protein elevation therapies for cancer and immune-mediated diseases.
Nurix Therapeutics is discontinuing one of its BTK-targeted programs while momentum builds behind a partnered asset that is moving into Phase 3, sharpening the company's focus on its remaining degraders.